GB0906579D0 - Pharmaceuticals, compositions and methods of making and using the same - Google Patents

Pharmaceuticals, compositions and methods of making and using the same

Info

Publication number
GB0906579D0
GB0906579D0 GBGB0906579.8A GB0906579A GB0906579D0 GB 0906579 D0 GB0906579 D0 GB 0906579D0 GB 0906579 A GB0906579 A GB 0906579A GB 0906579 D0 GB0906579 D0 GB 0906579D0
Authority
GB
United Kingdom
Prior art keywords
making
methods
compositions
compounds
pharmaceuticals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0906579.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Priority to GBGB0906579.8A priority Critical patent/GB0906579D0/en
Publication of GB0906579D0 publication Critical patent/GB0906579D0/en
Priority to KR1020117001954A priority patent/KR101680390B1/ko
Priority to KR1020187031734A priority patent/KR102008640B1/ko
Priority to CN200980124230.6A priority patent/CN102076692B/zh
Priority to KR1020167026831A priority patent/KR20160116054A/ko
Priority to PCT/GB2009/001605 priority patent/WO2009156737A1/en
Priority to MX2010013841A priority patent/MX2010013841A/es
Priority to PL09769578T priority patent/PL2321321T3/pl
Priority to PT09769578T priority patent/PT2321321E/pt
Priority to DK09769578.7T priority patent/DK2321321T3/da
Priority to ES09769578T priority patent/ES2382154T3/es
Priority to AT09769578T priority patent/ATE544767T1/de
Priority to EA201100079A priority patent/EA018803B1/ru
Priority to BRPI0910182A priority patent/BRPI0910182B8/pt
Priority to JP2011515594A priority patent/JP5559162B2/ja
Priority to NZ590590A priority patent/NZ590590A/en
Priority to CA2727444A priority patent/CA2727444C/en
Priority to AU2009263976A priority patent/AU2009263976B2/en
Priority to US12/997,721 priority patent/US8450328B2/en
Priority to EP09769578A priority patent/EP2321321B1/en
Priority to IL210071A priority patent/IL210071A/en
Priority to ZA2011/00526A priority patent/ZA201100526B/en
Priority to US13/889,921 priority patent/US8987279B2/en
Priority to US14/618,829 priority patent/US9376443B2/en
Priority to IL243574A priority patent/IL243574B/en
Priority to US15/172,126 priority patent/US9765080B2/en
Priority to US15/682,346 priority patent/US10106547B2/en
Priority to US16/132,411 priority patent/US10538526B2/en
Priority to US16/700,160 priority patent/US10875868B2/en
Priority to US17/088,325 priority patent/US11466019B2/en
Priority to US17/895,037 priority patent/US20230100842A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
GBGB0906579.8A 2008-06-25 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same Ceased GB0906579D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GBGB0906579.8A GB0906579D0 (en) 2009-04-16 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same
AU2009263976A AU2009263976B2 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists
JP2011515594A JP5559162B2 (ja) 2008-06-25 2009-06-25 プリン受容体アンタゴニストとしてのトリアゾロ［４，５−ｄ］ピリミジン誘導体およびその使用
NZ590590A NZ590590A (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyrimidine derivatives and their use as purine receptor antagonists
CN200980124230.6A CN102076692B (zh) 2008-06-25 2009-06-25 三唑并[4，5-d]嘧啶衍生物及其作为嘌呤受体拮抗剂的应用
KR1020167026831A KR20160116054A (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
PCT/GB2009/001605 WO2009156737A1 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists
MX2010013841A MX2010013841A (es) 2008-06-25 2009-06-25 Derivados de triazolo[4,5-d]pirimidina y su uso como antagonistas del receptor de purina.
PL09769578T PL2321321T3 (pl) 2008-06-25 2009-06-25 Pochodne triazolo [4,5-d]pirymidyny i ich zastosowanie jako antagoniści receptora purynowego
PT09769578T PT2321321E (pt) 2008-06-25 2009-06-25 Derivados de triazolo[4,5-d]piramidina e seu uso como anatagonistas do receptor purina
DK09769578.7T DK2321321T3 (da) 2008-06-25 2009-06-25 Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
ES09769578T ES2382154T3 (es) 2008-06-25 2009-06-25 Derivados de triazolo [4,5-D]piramidina y su uso como antagonistas de los receptores de purina
AT09769578T ATE544767T1 (de) 2008-06-25 2009-06-25 Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
EA201100079A EA018803B1 (ru) 2008-06-25 2009-06-25 Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
BRPI0910182A BRPI0910182B8 (pt) 2008-06-25 2009-06-25 composto de fórmula (i), composição farmacêutica e uso de um composto
KR1020117001954A KR101680390B1 (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
CA2727444A CA2727444C (en) 2008-06-25 2009-06-25 Triazolo [4,5-d] pyramidine derivatives and their use as purine receptor antagonists
EP09769578A EP2321321B1 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d]pyramidine derivatives and their use as purine receptor antagonists
KR1020187031734A KR102008640B1 (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
US12/997,721 US8450328B2 (en) 2008-06-25 2009-06-25 Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists
IL210071A IL210071A (en) 2008-06-25 2010-12-16 Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
ZA2011/00526A ZA201100526B (en) 2008-06-25 2011-01-20 Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
US13/889,921 US8987279B2 (en) 2008-06-25 2013-05-08 Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists
US14/618,829 US9376443B2 (en) 2008-06-25 2015-02-10 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
IL243574A IL243574B (en) 2008-06-25 2016-01-11 A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors
US15/172,126 US9765080B2 (en) 2008-06-25 2016-06-02 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US15/682,346 US10106547B2 (en) 2008-06-25 2017-08-21 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US16/132,411 US10538526B2 (en) 2008-06-25 2018-09-15 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US16/700,160 US10875868B2 (en) 2008-06-25 2019-12-02 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
US17/088,325 US11466019B2 (en) 2008-06-25 2020-11-03 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
US17/895,037 US20230100842A1 (en) 2009-04-06 2022-08-24 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0906579.8A GB0906579D0 (en) 2009-04-16 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
GB0906579D0 true GB0906579D0 (en) 2009-05-20

Family

ID=40750727

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0906579.8A Ceased GB0906579D0 (en) 2008-06-25 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same

Country Status (20)

Country Link
US (9) US8450328B2 (https=)
EP (1) EP2321321B1 (https=)
JP (1) JP5559162B2 (https=)
KR (3) KR102008640B1 (https=)
CN (1) CN102076692B (https=)
AT (1) ATE544767T1 (https=)
AU (1) AU2009263976B2 (https=)
BR (1) BRPI0910182B8 (https=)
CA (1) CA2727444C (https=)
DK (1) DK2321321T3 (https=)
EA (1) EA018803B1 (https=)
ES (1) ES2382154T3 (https=)
GB (1) GB0906579D0 (https=)
IL (2) IL210071A (https=)
MX (1) MX2010013841A (https=)
NZ (1) NZ590590A (https=)
PL (1) PL2321321T3 (https=)
PT (1) PT2321321E (https=)
WO (1) WO2009156737A1 (https=)
ZA (1) ZA201100526B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
MX2014014308A (es) * 2012-05-30 2015-02-12 Hoffmann La Roche Pirrolidino heterociclos.
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
EP3393475B1 (en) * 2015-12-24 2025-02-05 Corvus Pharmaceuticals, Inc. Ciforadent alone or in combination with atezolizumab for use in treating cancer
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
BR112019011065A2 (pt) 2016-12-03 2019-10-01 Juno Therapeutics Inc métodos para determinação da dosagem de células t car
CN110248678A (zh) 2016-12-03 2019-09-17 朱诺治疗学股份有限公司 调节car-t细胞的方法
HUE064141T2 (hu) 2017-01-20 2024-02-28 Arcus Biosciences Inc Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
US10654825B2 (en) * 2017-03-30 2020-05-19 Corvus Pharmaceuticals, Inc. Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof
US20190022096A1 (en) * 2017-04-04 2019-01-24 Corvus Pharmaceuticals, Inc. Methods of treating cancer
EP3606531A4 (en) * 2017-04-04 2021-04-28 Corvus Pharmaceuticals, Inc. METHOD OF TREATMENT OF CANCER
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
KR20200096921A (ko) * 2017-11-06 2020-08-14 코버스 파마슈티칼스, 인크. 암 치료를 위한 아데노신 경로 억제제
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
WO2019152798A1 (en) * 2018-02-01 2019-08-08 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
EP3520782A3 (en) 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
WO2019154294A1 (zh) 2018-02-06 2019-08-15 江苏恒瑞医药股份有限公司 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US12116635B2 (en) 2018-07-12 2024-10-15 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US12174192B2 (en) 2018-07-12 2024-12-24 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
BE1026612B1 (fr) 2018-09-27 2020-07-02 Iteos Therapeutics S A Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine
WO2020068583A1 (en) * 2018-09-27 2020-04-02 Corvus Pharmaceuticals, Inc. Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof
IL281802B2 (en) 2018-09-27 2025-10-01 iTeos Belgium SA Use of an ENT family transporter inhibitor in cancer treatment and its combination with an adenosine receptor antagonist
EP3873937A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
IL283218B2 (en) 2018-11-16 2025-11-01 Juno Therapeutics Inc Dosing methods of engineered T cells for the treatment of malignant B cells
AU2019383948A1 (en) * 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
PT3886875T (pt) 2018-11-30 2024-06-27 Juno Therapeutics Inc Métodos para tratamento utilizando terapia celular adotiva
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
SG11202107976SA (en) 2019-01-29 2021-08-30 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
MX2022003719A (es) 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
KR20210061202A (ko) * 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
US20230089247A1 (en) * 2019-12-24 2023-03-23 Zydus Lifesciences Limited Novel compounds suitable for the treatment of dyslipidemia
EP4110784A1 (en) 2020-02-26 2023-01-04 iTeos Belgium SA Pyrimido[5,4-d]pyrimidine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists
KR20230007369A (ko) 2020-04-07 2023-01-12 아이테오스 벨지움 에스에이 암의 치료를 위한 ent 저해제로서의 거대환식 다이아민 유도체 및 이와 아데노신 수용체 길항제와의 조합물
JP2023522857A (ja) 2020-04-10 2023-06-01 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
EP4294948A1 (en) 2021-02-17 2023-12-27 iTeos Belgium SA Compounds, compositions and methods of treatment thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
KR20250135354A (ko) 2022-12-13 2025-09-12 주노 쎄러퓨티크스 인코퍼레이티드 Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도
WO2024134541A1 (en) 2022-12-20 2024-06-27 iTeos Belgium SA Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers
TW202523332A (zh) 2023-11-14 2025-06-16 比利時商艾托斯比利時公司 Ｅｎｔ１抑制劑與檢查點抑制劑組合
WO2025170158A1 (ko) * 2024-02-08 2025-08-14 아이리드비엠에스 주식회사 Cxcr7 수용체 조절제 및 이의 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56131587A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd 7-substituted triazolopyrimidine derivative and its preparation
JPS56131586A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd Triazolopyrimidine derivative and its preparation
JPS5962595A (ja) 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５，７―トリ置換―トリアゾロピリミジン誘導体
DE3304330A1 (de) 1983-02-09 1984-08-09 Basf Ag, 6700 Ludwigshafen Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung
JPS60140335A (ja) 1983-12-28 1985-07-25 Konishiroku Photo Ind Co Ltd 熱現像カラ−感光材料
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
TW427996B (en) 1995-07-11 2001-04-01 Astra Pharma Prod Novel triazolopyrimidines and their use as medicaments
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された６，５―ヘテロ―二環式誘導体
AU8181098A (en) 1997-07-03 1999-01-25 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
DE19736535C1 (de) 1997-08-22 1999-01-28 Basf Coatings Ag Basislackzusammensetzung sowie Verfahren zur Herstellung von mehrschichtigen Überzügen
US5939432A (en) 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
EP0975345A1 (en) 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DK3421471T3 (da) * 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same

Also Published As

Publication number Publication date
JP5559162B2 (ja) 2014-07-23
AU2009263976A1 (en) 2009-12-30
CA2727444A1 (en) 2009-12-30
JP2011525898A (ja) 2011-09-29
US20170342081A1 (en) 2017-11-30
US10538526B2 (en) 2020-01-21
KR102008640B1 (ko) 2019-08-07
US20110172252A1 (en) 2011-07-14
US20170088552A1 (en) 2017-03-30
PT2321321E (pt) 2012-05-15
ZA201100526B (en) 2012-04-25
PL2321321T3 (pl) 2012-07-31
US8450328B2 (en) 2013-05-28
IL243574B (en) 2019-03-31
US20230100842A1 (en) 2023-03-30
NZ590590A (en) 2011-12-22
KR20110057122A (ko) 2011-05-31
US20210115054A1 (en) 2021-04-22
US9376443B2 (en) 2016-06-28
EP2321321B1 (en) 2012-02-08
EA201100079A1 (ru) 2011-08-30
CN102076692B (zh) 2014-10-22
CN102076692A (zh) 2011-05-25
KR20180122482A (ko) 2018-11-12
BRPI0910182B1 (pt) 2020-10-27
US10875868B2 (en) 2020-12-29
BRPI0910182A2 (pt) 2017-05-30
DK2321321T3 (da) 2012-05-21
KR20160116054A (ko) 2016-10-06
US20130245044A1 (en) 2013-09-19
CA2727444C (en) 2017-01-17
US9765080B2 (en) 2017-09-19
KR101680390B1 (ko) 2016-11-28
EA018803B1 (ru) 2013-10-30
ATE544767T1 (de) 2012-02-15
US8987279B2 (en) 2015-03-24
WO2009156737A1 (en) 2009-12-30
US20190031668A1 (en) 2019-01-31
IL210071A0 (en) 2011-02-28
EP2321321A1 (en) 2011-05-18
ES2382154T3 (es) 2012-06-05
IL210071A (en) 2016-02-29
US20150291602A1 (en) 2015-10-15
MX2010013841A (es) 2011-02-25
US20200172547A1 (en) 2020-06-04
US10106547B2 (en) 2018-10-23
US11466019B2 (en) 2022-10-11
AU2009263976B2 (en) 2013-12-05
BRPI0910182B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN02177A (https=)
IN2012DN00754A (https=)
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
CA2871471C (en) Dna-pk inhibitors
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
MX2013005549A (es) Aminas heterociclicas y sus usos.
TN2013000529A1 (en) Trpm8 antagonists and their use in treatments
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
UA96037C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)